Anti-TNF-α therapy with infliximab in spondyloarthritides

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 9-19

  Baraliakos, Xenofon ^a   Braun, Juergen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Efficacy; Infliximab; Safety; Spondyloarthritides

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; DIPHENHYDRAMINE; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; COCCIDIOIDOMYCOSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; ENTHESITIS; FOLLOW UP; HUMAN; INFECTION; INJECTION SITE REACTION; IRIDOCYCLITIS; JOINT STIFFNESS; LONG TERM CARE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATHOGENESIS; PHYSIOTHERAPY; PRACTICE GUIDELINE; PSORIASIS; REACTIVE ARTHRITIS; RELAPSE; REMISSION; RETROPHARYNGEAL ABSCESS; REVIEW; SEPSIS; SPONDYLOARTHROPATHY; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; SPONDYLARTHRITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649165573     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.61     Document Type: Review

References (126)

1. Olivieri I, van Tubergen A, Salvarani C, van der Linden S. Seronegative spondyloarthritides. Best Pract. Res. Clin. Rheumatol. 16(5), 723-739 (2002).
2. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41(1), 58-67 (1998).
3. Brandt J, Bollow M, Haberle J et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 38(9), 831-836 (1999).
4. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middleaged population of Tromso, northern Norway. Ann. Rheum. Dis. 44(6), 359-367 (1985).
5. Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J. Rheumatol. 26(12), 2622-2627 (1999).
6. Rudwaleit M, Haibel H, Baraliakos X et al. The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort. Arthritis Rheum. 60(3), 717-727 (2009).
7. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis -results from the German rheumatological database. German Collaborative Arthritis Centers. J. Rheumatol. 27(3), 613-622 (2000).
8. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 12(4), 247-255 (1999).
9. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann. Rheum. Dis. 60(3), 199-206 (2001). (Pubitemid 32260599)
10. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann. Rheum. Dis. 60(4), 353-358 (2001).
11. Chorus AM, Boonen A, Miedema HS, van der Linden S. Employment perspectives of patients with ankylosing spondylitis. Ann. Rheum. Dis. 61(8), 693-699 (2002).
12. Boonen A, van der Heijde D, Landewe R et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann. Rheum. Dis. 61(5), 429-437 (2002).
13. Boonen A, van der Heijde D, Landewe R et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann. Rheum. Dis. 62(8), 741-747 (2003). (Pubitemid 36886408)
14. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 46(1), 223-231 (2002).
15. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor a treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann. Rheum. Dis. 63(12), 1670-1672 (2004).
16. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum. Dis. Clin. North Am. 24(4), 737-751, viii (1998).
17. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum. Dis. Clin. North Am. 21(1), 117-128 (1995).
18. Sieper J, Klopsch T, Richter M et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann. Rheum. Dis. 67(3), 323-329 (2008).
19. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J. Rheumatol. 29(7), 1420-1425 (2002).
20. van Tubergen A, Landewe R, van der Heijde D et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 45(5), 430-438 (2001).
21. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-a therapy and other novel approaches. Arthritis Res. 4(5), 307-321 (2002).
22. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J. Anatomic structures involved in early-and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 48(5), 1374-1384 (2003).
23. Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr. Opin. Rheumatol. 21(4), 324-334 (2009).
24. Breban M, Ravaud P, Claudepierre P et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 58(1), 88-97 (2008).
25. Li EK, Griffith JF, Lee VW et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47(9), 1358-1363 (2008).
26. Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum. 57(1), 133-139 (2007).
27. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr. Opin. Rheumatol. 8(4), 275-287 (1996).
28. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 41(4), 694-700 (1998).
29. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 37(7), 1039-1045 (1994).
30. Laloux L, Voisin MC, Allain J et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 60(4), 316-321 (2001).
31. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38(4), 499-505 (1995).
32. Bollow M, Fischer T, Reisshauer H et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis -cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann. Rheum. Dis. 59(2), 135-140 (2000).
33. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor a in two patients with early disease and transforming growth factor b in three more advanced cases. Ann. Rheum. Dis. 65(6), 713-720 (2006).
34. Kruithof E, Van den Bosch F, Baeten D et al. Repeated infusions of infliximab, a chimeric anti-TNFa monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann. Rheum. Dis. 61(3), 207-212 (2002).
35. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J. Rheumatol. 28(7), 1605-1614 (2001).
36. Maksymowych WP, Jhangri GS, Lambert RG et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J. Rheumatol. 29(5), 959-965 (2002).
37. Breban M, Vignon E, Claudepierre P. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of an open label study. Presented at: Annual European Congress on Rheumatology, European League Against Rheumatism (EULAR). Prague, Czech Republic, 13-16 June 2001.
38. Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann. Rheum. Dis. 62(12), 1239-1240 (2003).
39. Braun J, Brandt J, Listing J et al. Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebocontrolled trial. Arthritis Rheum. 48(8), 2224-2233 (2003).
40. Temekonidis TI, Alamanos Y, Nikas SN et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann. Rheum. Dis. 62(12), 1218-1220 (2003).
41. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum. 43(6), 1346-1352 (2000).
42. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21(12), 2286-2291 (1994).
43. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313), 1187-1193 (2002).
44. Breban M, Vignon E, Claudepierre P et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41(11), 1280-1285 (2002).
45. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo controlled trial (ASSERT). Arthritis Rheum. 52(2), 582-591 (2005).
46. Braun J, Sieper J, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylits: 102 week results of the ASSERT trial. Ann. Rheum. Dis. 65(Suppl. II), 87 (2006).
47. Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann. Rheum. Dis. 64(2), 229-234 (2005).
48. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNF antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44(5), 670-676 (2005).
49. Braun J, Baraliakos X, Listing J et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann. Rheum. Dis. 67(3), 340-345 (2008).
50. Baraliakos X, Listing J, Fritz C et al. Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years -evidence for different response to anti-TNFa therapy. Ann. Rheum. Dis. 67(Suppl. II), 375 (2008).
51. Baraliakos X, Listing J, Brandt J et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. 7(3), R439-R444 (2005).
52. Braun J, Deodhar A, Dijkmans B et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 59(9), 1270-1278 (2008).
53. Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. 16(4), 573-604 (2002).
54. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 48(4), 1126-1136 (2003).
55. Braun J, Landewe R, Hermann KG et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 54(5), 1646-1652 (2006).
56. Creemers M, Franssen M, Hof Mv M, Gribnau F, Van De Putte L, Van Riel P. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann. Rheum. Dis. 64, 127-129 (2005).
57. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab. Ann. Rheum. Dis. 64(10), 1462-1466 (2005).
58. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-a antibody infliximab. Rheumatology (Oxford) 46(9), 1450-1453 (2007).
59. Heijde DV, Landewe R, Baraliakos X et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58(10), 3063-3070 (2008).
60. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 58(3), 649-656 (2008).
61. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res. Ther. 10(5), R104 (2008).
62. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 60(1), 93-102 (2009).
63. Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis -evidence for major individual variations in a large proportion of patients. J. Rheumatol. 36(5), 997-1002 (2009).
64. Jois RN, Leeder J, Gibb A et al. Low-dose infliximab treatment for ankylosing spondylitis -clinically-and cost-effective. Rheumatology (Oxford) 45(12), 1566-1569 (2006).
65. Sidiropoulos P, Kritikos HD, Siakka P et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin. Exp. Rheumatol. 23(4), 513-516 (2005).
66. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-TNF therapy on hospitalizations and days on sick leave in patients with ankylosing spondylitis. Arthritis Rheum. (In press) (2009).
67. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the costeffectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 43(9), 1158-1166 (2004).
68. van der Heijde D, De Vlam K, Burmester G et al. Infliximab improves productivity in employed patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Presented at: Annual meeting of the European League Against Rheumatism (EULAR). Berlin, Germany, 9-12 June 2004.
69. Hidding A, van der Linden S, de Witte L. Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease. Clin. Rheumatol. 12(3), 334-340 (1993).
70. Hidding A, van der Linden S, Boers M et al. Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res. 6(3), 117-125 (1993).
71. Hidding A, van der Linden S, Gielen X, de Witte L, Dijkmans B, Moolenburgh D. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res. 7(2), 90-96 (1994). (Pubitemid 24181338)
72. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis -a randomized controlled trial. J. Rheumatol. 17(2), 228-233 (1990).
73. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith CH. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis -an 8-month followup. J. Rheumatol. 21(2), 261-263 (1994).
74. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 34(10), 1218-1227 (1991).
75. Rudwaleit M, Landewe R, van der Heijde D et al. The Development of Assessment of SpondyloArthritis International Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann. Rheum. Dis. 68, 777-783 (2009).
76. Rudwaleit M, van der Heijde D, Landewe R et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): validation and final selection. Ann. Rheum. Dis. 68, 765-767 (2009).
77. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. 59(6), 428-433 (2000).
78. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-a monoclonal antibody infliximab. J. Rheumatol. 29(1), 118-122 (2002).
79. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 44(9), 2112-2117 (2001).
80. Barkham N, Keen HI, Coates LC et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60(4), 946-954 (2009).
81. Haibel H, Rudwaleit M, Listing J et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, doubleblind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 58(7), 1981-1991 (2008).
82. D'Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. 46(3), 840-841; author reply 1-3 (2002).
83. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 53(6), 856-863 (2005).
84. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum. 48(2), 523-533 (2003).
85. Marzo-Ortega H, McGonagle D, Jarrett S et al. Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann. Rheum. Dis. 64, 1568-1575 (2005).
86. Braun J, Sieper J. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. BioDrugs 17(3), 187-199 (2003).
87. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 42(10), 1138-1148 (2003).
88. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. 61(4), 298-304 (2002).
89. Canete JD, Pablos JL, Sanmarti R et al. Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 50(5), 1636-1641 (2004).
90. Antoni C, Dechant C, Hanns-Martin Lorenz PD et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 47(5), 506-512 (2002). (Pubitemid 35291372)
91. Antoni CE, Kavanaugh A, van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol. 35(5), 869-876 (2008).
92. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64(8), 1150-1157 (2005).
93. Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J. Rheumatol. 12(2), 287-293 (1985). (Pubitemid 15025371)
94. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor a agents. Arthritis Rheum. 57(4), 639-647 (2007).
95. Generini S, Giacomelli R, Fedi R et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63(12), 1664-1669 (2004).
96. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5(2), 119-133 (1999).
97. Song IH, Appel H, Haibel H et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J. Rheumatol. 35(3), 532-536 (2008).
98. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52(8), 2447-2451 (2005).
99. Rudwaleit M, Rodevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. (2008) (Epub ahead of print).
100. Davis JC, van der Heijde DM, Braun J et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann. Rheum. Dis. 64(11), 1557-1562 (2005).
101. Schafranski MD. Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection. Rheumatol. Int. (2009) (Epub ahead of print).
102. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand. J. Rheumatol. 32(2), 122-124 (2003).
103. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20(6 Suppl. 28), S152-S157 (2002).
104. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum. 48(11), 3013-3022 (2003).
105. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104 (2001).
106. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48(8), 2122-2127 (2003).
107. Baeten D, Kruithof E, Van den Bosch F et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann. Rheum. Dis. 62(9), 829-834 (2003).
108. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1), 19-31 (2004).
109. Wagner CL, Schantz A, Barnathan E et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev. Biol. (Basel) 112, 37-53 (2003).
110. Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor a antagonists. Arthritis Rheum. 50(6), 1959-1966 (2004).
111. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98(6), 1315-1324 (2003).
112. Hyrich KL, Watson KD, Isenberg DA, Symmons DP. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 47(10), 1441-1443 (2008).
113. Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52(7), 1986-1992 (2005). (Pubitemid 40994319)
114. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann. Rheum. Dis. 61(4), 375-376 (2002).
115. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor a-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 46(7), 1965-1968 (2002).
116. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-a inhibition therapy. Foot Ankle Int. 25(5), 331-335 (2004).
117. Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal Crohn's disease. Int. J. Colorectal Dis. 23(10), 965-969 (2008).
118. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J. Rheumatol. 31(1), 107-109 (2004).
119. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50(6), 1740-1751 (2004). (Pubitemid 38725085)
120. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46(12), 3151-3158 (2002).
121. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
122. Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130(4), 1054-1061 (2006).
123. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 33(4), 283-288 (2004).
124. Mease PJ, Ritchlin CT, Martin RW et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J. Rheumatol. 31(7), 1356-1361 (2004).
125. Hansen KE, Hildebrand JP, Genovese MC et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31(6), 1098-1102 (2004).
126. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann. Rheum. Dis. 62(12), 1195-1198 (2003).